Buy Harvoni

Harvoni

Harvoni: What Is This Medication?

Harvoni is a brand-name antiviral medication that contains the two active ingredients ledipasvir and sofosbuvir. It is approved for the treatment of chronic hepatitis C virus (HCV) infection in adults. Harvoni is supplied as a single-pill tablet containing 90 mg ledipasvir / 400 mg sofosbuvir. In Hong Kong the product is prescription-only and is regulated by the Department of Health. The medication is manufactured by Gilead Sciences.

How Harvoni Works in the Body

Harvoni combines two agents that stop HCV from replicating:

• Ledipasvir blocks the viral protein NS5A, a protein that helps the virus assemble its replication complex and attach to liver cells. By inhibiting NS5A, ledipasvir disrupts the formation of new viral particles.
• Sofosbuvir is a nucleotide-analogue that targets the viral polymerase NS5B. After the tablet is absorbed, sofosbuvir is converted inside liver cells to its active form, which is then incorporated into the viral RNA chain, causing premature termination of viral replication.

Together, these mechanisms provide a potent, dual-action blockade of HCV replication, leading to rapid decline of viral load. The drug reaches peak plasma concentrations within about 4-5 hours and maintains therapeutic levels with once-daily dosing.

Conditions Treated by Harvoni

Harvoni is approved by the Hong Kong Department of Health for the following indications in adults:

• Chronic HCV genotype 1 infection (including subtypes 1a and 1b) with or without compensated cirrhosis.
• Chronic HCV genotype 4 infection in patients without decompensated liver disease.

Treatment duration is typically 8 weeks for treatment-naïve patients without cirrhosis, and 12 weeks for patients with cirrhosis, prior treatment experience, or certain genotype 1 sub-populations. The regimen is taken as one tablet daily, with or without food.

Evidence-Based Off-Label Uses

Some clinical studies have examined Harvoni in HCV genotypes 2, 3, 5, and 6, but these uses are not approved by regulatory agencies in Hong Kong. When used off-label, treatment decisions must be made under close medical supervision, weighing the limited evidence against potential risks.

Disclaimer: Off-label use requires individualized risk assessment by a qualified healthcare professional.

Who Should (and Should Not) Use Harvoni?

Ideal Candidates

• Adults (≥ 18 years) with confirmed chronic HCV genotype 1 or 4 infection.
• Patients with stable liver function (Child-Pugh A) who can adhere to daily oral therapy.

Absolute Contraindications

• Known hypersensitivity to ledipasvir, sofosbuvir, or any tablet excipients.
• Co-administration with amiodarone or other strong P-glycoprotein (P-gp) inhibitors without appropriate monitoring, due to risk of serious bradycardia.
• Pregnant women: safety during pregnancy has not been established. Harvoni should be avoided unless the benefit outweighs the risk and the patient is under specialist care.
• Children weighing less than 35 kg or younger than 12 years, as safety and efficacy have not been demonstrated.

Relative Contraindications & Precautions

• Severe renal impairment (eGFR < 30 mL/min/1.73 m²): limited data; dose adjustment is not recommended and alternative regimens may be considered.
• Decompensated cirrhosis (Child-Pugh B or C): Harvoni is not indicated; other antiviral combinations are preferred.
• Co-administration with strong inducers of P-gp (e.g., carbamazepine, St. John’s wort, rifampin) may reduce Harvoni exposure and compromise efficacy.

Patients with any of the above conditions should discuss alternative treatment options with their hepatologist or infectious-disease specialist.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Fatigue - generally mild and transient.
• Headache - reported in many patients; usually resolves without intervention.
• Nausea - often improves after the first few days of therapy.
• Diarrhea - occasional, self-limiting.

Serious Adverse Events

• Bradycardia - may occur when Harvoni is taken with amiodarone or other P-gp inhibitors; requires immediate medical evaluation.
• Elevated hepatic enzymes - rare but may signal liver injury; monitor liver function during treatment.
• Allergic reactions - include rash, itching, or swelling; discontinue if severe.

Drug Interactions

• Contraindicated: Amiodarone (risk of severe bradycardia).
• Major interactions: Strong P-gp inducers such as carbamazepine, St. John’s wort, rifampin can lower Harvoni concentrations.
• Moderate interactions: Antacids containing aluminum or magnesium may reduce absorption; separate dosing by at least 4 hours.

Patients should provide a complete medication list-including over-the-counter drugs, supplements, and herbal products-to their prescriber before starting Harvoni.

Food and Lifestyle Interactions

• Harvoni can be taken with or without food; a high-fat meal does not significantly alter exposure.
• No specific alcohol restriction, but patients with advanced liver disease should limit alcohol intake.
• No known effects on driving or the use of machinery.

How to Take Harvoni

• Standard dosing: One Harvoni tablet (90 mg ledipasvir / 400 mg sofosbuvir) taken once daily.
• Duration: 8 weeks for treatment-naïve, non-cirrhotic genotype 1 patients; 12 weeks for cirrhotic patients, prior treatment experience, or genotype 4 infection.
• Special populations:
• Renal impairment: Not recommended for eGFR < 30 mL/min/1.73 m²; consult a specialist.
• Pregnancy & lactation: Avoid unless the benefit justifies the potential risk.
• Administration: Swallow the tablet whole with water; do not crush or split.
• Missed dose: Take the missed tablet as soon as remembered, unless it is close to the next scheduled dose-do not double the dose.
• Overdose: Symptoms may include nausea, vomiting, and dizziness. Seek emergency medical care; supportive measures are the mainstay of treatment.
• Discontinuation: No tapering is required. If therapy is stopped early, the risk of viral relapse increases; discuss further management with a clinician.

Monitoring and Follow-Up

• Baseline assessments: HCV RNA viral load, genotype, liver function tests (ALT, AST, bilirubin), and renal function.
• During therapy: HCV RNA testing at week 4 (optional) and at the end of treatment to confirm viral suppression.
• Post-treatment: A sustained virologic response (SVR) is assessed 12 weeks after completing therapy; a negative HCV RNA indicates cure.
• Safety labs: Periodic liver enzymes and renal function tests, especially in patients with existing liver disease or impaired kidneys.

Regular follow-up visits with a hepatology or infectious-disease specialist are essential to ensure treatment success and manage any adverse events.

Storage and Handling

• Store the tablet at room temperature (20-25 °C), away from moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use the medication past the printed expiration date.
• Dispose of unused tablets according to local pharmacy-take-back programs or the instructions on the package label.

Medication-Specific Glossary

NS5A

A non-structural viral protein essential for hepatitis C replication and assembly; ledipasvir’s target.

NS5B polymerase

The RNA-dependent RNA polymerase of HCV that synthesizes viral RNA; inhibited by sofosbuvir.

Sustained Virologic Response (SVR)

The absence of detectable HCV RNA 12 weeks after completing therapy, regarded as a cure.

P-glycoprotein (P-gp)

A transporter protein that pumps certain drugs out of cells; strong P-gp inducers can lower Harvoni levels.

Medical Disclaimer

This article provides educational information about Harvoni and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.